We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




First and Only Fully Automated Assay of Its Kind Advances Diagnostics for Bleeding Disorder

By LabMedica International staff writers
Posted on 07 Oct 2022

Von Willebrand disease (VWD) is the most common inherited bleeding disorder, affecting approximately one percent of the population - and both men and women equally. More...

Physicians diagnose VWD based on bleeding symptoms, patient history, and lab test results, including von Willebrand factor (VWF) activity. Until now, VWF activity assays were disadvantaged with low precision and sensitivity, and with difficulties in diagnosing certain VWF polymorphisms. To help address these deficiencies, the International Society on Thrombosis and Hemostasis (ISTH) recently published a guideline changing its recommendation for VWF activity assays from the ristocetin cofactor assay (VWF:RCo) to newer assays (VWF:GPIbM) that directly measure the platelet binding activity of VWF without the need of ristocetin. Now, Siemens Healthineers (Erlangen, Germany) has announced that its INNOVANCE VWF Ac assay - the sole fully automated assay of its kind (VWF:GPIbM) - is now available to U.S. laboratories for use on the company’s BCS XP System, as well as on the Sysmex CS-2500 and CS-5100 hemostasis analyzers.

Siemens’ INNOVANCE VWF Ac assay is the only fully automated, commercially available VWF activity assay for laboratories in the U.S. that uses the guideline recommended VWF:GPIbM technology. The INNOVANCE VWF Ac assay is a liquid, ready-to-use assay, and offers laboratorians a broad measuring range with a lower limit of quantitation compared to the VWF:RCo technology. Currently deployed in many European laboratories, the assay's VWF:GPIbM technology allows for a more accurate functional assessment of VWF activity with greater precision and heightened sensitivity, and the ability to detect VWF variants that otherwise might be missed compared to other commercially available VWF assay technologies.

“After the positive experience we had using this assay in a study, we as caregivers in the U.S. are urgently waiting to use the INNOVANCE VWF Ac assay to diagnose our patients, as we believe it supports improved von Willebrand disease diagnosis and patient management - particularly now given the new recommendations from the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD,” said Dr. Steven Pipe, Professor of Pediatrics and Pathology from the University of Michigan, Ann Arbor.

Related Links:
Siemens Healthineers 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.